PubMed

Characteristics of pivotal clinical trials of FDA-approved endovascular devices between 2000 and 2018: An interrupted time series analysis.

PMID: 37008598 · 2023-02-03

J, o, h, n, , T, , M, o, o, n, ;, , M, e, n, e, l, a, o, s, , K, o, n, s, t, a, n, t, i, n, i, d, i, s, ;, , N, e, v, o, n, , S, o, n, g, ;, , N, a, r, i, m, a, n, , N, e, z, a, m, i, ;, , B, i, l, l, , S, , M, a, j, d, a, l, a, n, y, ;, , A, l, l, e, n, , H, e, r, r, ;, , G, a, r, y, , S, i, s, k, i, n

ЖурналJournal of clinical and translational science

Год2023-02-03

PMID37008598

Аннотация

The Food and Drug Administration (FDA) reviews safety, efficacy, and the quality of medical devices through its regulatory process. The FDA Safety and Innovation Act (FDASIA) of 2012 was aimed at accelerating the regulatory process for medical devices. The purpose of our study was to (1) quantify characteristics of pivotal clinical trials (PCTs) supporting the premarket approval of endovascular medical devices and (2) analyze trends over the last two decades in light of the FDASIA. We surveyed t

Официальный источник

Открыть в PubMed →

Данные получены из PubMed / NCBI. Полный текст и наиболее актуальную информацию всегда смотрите в официальной записи.